Home | Welcome to Contract Pharma   
Last Updated Thursday, September 18 2014

Topics - APIs

Refine by Date:
From: To:
Published September 4, 2014
Complies with the quality GMP & GDP standards Read More »
Published August 20, 2014
Expands geographic scale, manufacturing and lyophilization capabilities Read More »
Published August 18, 2014
To manufacture API for branded commercial drug Read More »
Published August 5, 2014
Ireland facility gains pre-approval Read More »
Published July 22, 2014
Will support a portfolio of drug substance campaigns Read More »
Published July 22, 2014
Will produce NME for U.S. market Read More »
Published July 21, 2014
Phase IIa trial scheduled for 2014 Read More »
Published June 23, 2014
Expands GMP manufacturing services for APIs Read More »
Published May 20, 2014
Secures additional manufacturing capacity for Patiromer Read More »
Published May 13, 2014
Provided process development and production of Neuronascent’s lead candidate NNI-362 Read More »
Published May 1, 2014
EDQM certifies Dimethyl Sulfoxide suitability Read More »
Published April 9, 2014
Aims to support long-term growth efforts Read More »
Published April 8, 2014
To provide APIC with additional capacity for APIs and intermediates Read More »
By Kristin Brooks
Published March 24, 2014
Expands custom API products and services Read More »
By Kristin Brooks
Published March 11, 2014
Aims to sell generic Nexium in the U.S., despite regulatory restrictions Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On